<table frame="hsides" id="wherry1138991295002" xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 3Major Outcomes of the NSABP P-1 Trial</caption>
<colgroup>
<col width="98*"></col>
<col width="99*"></col>
<col width="100*"></col>
<col width="100*"></col>
<col width="100*"></col>
<col width="99*"></col>
<col width="100*"></col>
</colgroup>
<thead>
<tr><td valign="top"></td><td align="center" colspan="2" valign="top"><paragraph><content stylecode="bold"># of Events</content></paragraph></td><td align="center" colspan="2" valign="top"><paragraph><content stylecode="bold">Rate/1000 Women/Year</content></paragraph></td><td align="center" colspan="2" valign="top"><paragraph><content stylecode="bold">95% CI</content></paragraph></td></tr>
<tr><td valign="top"><paragraph><content stylecode="bold">Type of Event</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">Placebo</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">NOLVADEX</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">Placebo</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">NOLVADEX</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">RR</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">Limits</content></paragraph></td></tr>
</thead>
<tbody>
<tr><td valign="top"><paragraph><content stylecode="bold">Invasive Breast Cancer</content></paragraph></td><td valign="top"><paragraph>156</paragraph></td><td valign="top"><paragraph>86</paragraph></td><td valign="top"><paragraph>6.49</paragraph></td><td valign="top"><paragraph>3.58</paragraph></td><td valign="top"><paragraph>0.56</paragraph></td><td valign="top"><paragraph>0.43-0.72</paragraph></td></tr>
<tr><td valign="top"><paragraph>Age ≤49</paragraph></td><td valign="top"><paragraph>59</paragraph></td><td valign="top"><paragraph>38</paragraph></td><td valign="top"><paragraph>6.34</paragraph></td><td valign="top"><paragraph>4.11</paragraph></td><td valign="top"><paragraph>0.65</paragraph></td><td valign="top"><paragraph>0.43-0.98</paragraph></td></tr>
<tr><td valign="top"><paragraph>Age 50-59</paragraph></td><td valign="top"><paragraph>46</paragraph></td><td valign="top"><paragraph>25</paragraph></td><td valign="top"><paragraph>6.31</paragraph></td><td valign="top"><paragraph>3.53</paragraph></td><td valign="top"><paragraph>0.56</paragraph></td><td valign="top"><paragraph>0.35-0.91</paragraph></td></tr>
<tr><td valign="top"><paragraph>Age ≥60</paragraph></td><td valign="top"><paragraph>51</paragraph></td><td valign="top"><paragraph>23</paragraph></td><td valign="top"><paragraph>7.17</paragraph></td><td valign="top"><paragraph>3.22</paragraph></td><td valign="top"><paragraph>0.45</paragraph></td><td valign="top"><paragraph>0.27-0.74</paragraph></td></tr>
<tr><td valign="top"><paragraph><content stylecode="bold">Risk Factors for Breast Cancer History, LCIS</content></paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph> No</paragraph></td><td valign="top"><paragraph>140</paragraph></td><td valign="top"><paragraph>78</paragraph></td><td valign="top"><paragraph>6.23</paragraph></td><td valign="top"><paragraph>3.51</paragraph></td><td valign="top"><paragraph>0.56</paragraph></td><td valign="top"><paragraph>0.43-0.74</paragraph></td></tr>
<tr><td valign="top"><paragraph>Yes</paragraph></td><td valign="top"><paragraph>16</paragraph></td><td valign="top"><paragraph>8</paragraph></td><td valign="top"><paragraph>12.73</paragraph></td><td valign="top"><paragraph>6.33</paragraph></td><td valign="top"><paragraph>0.50</paragraph></td><td valign="top"><paragraph>0.21-1.17</paragraph></td></tr>
<tr><td valign="top"><paragraph><content stylecode="bold">History, Atypical Hyperplasia</content></paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>No</paragraph></td><td valign="top"><paragraph>138</paragraph></td><td valign="top"><paragraph>84</paragraph></td><td valign="top"><paragraph>6.37</paragraph></td><td valign="top"><paragraph>3.89</paragraph></td><td valign="top"><paragraph>0.61</paragraph></td><td valign="top"><paragraph>0.47-0.80</paragraph></td></tr>
<tr><td valign="top"><paragraph>Yes</paragraph></td><td valign="top"><paragraph>18</paragraph></td><td valign="top"><paragraph>2</paragraph></td><td valign="top"><paragraph>8.69</paragraph></td><td valign="top"><paragraph>1.05</paragraph></td><td valign="top"><paragraph>0.12</paragraph></td><td valign="top"><paragraph>0.03-0.52</paragraph></td></tr>
<tr><td valign="top"><paragraph><content stylecode="bold">No First Degree Relatives</content></paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>0</paragraph></td><td valign="top"><paragraph>32</paragraph></td><td valign="top"><paragraph>17</paragraph></td><td valign="top"><paragraph>5.97</paragraph></td><td valign="top"><paragraph>3.26</paragraph></td><td valign="top"><paragraph>0.55</paragraph></td><td valign="top"><paragraph>0.30-0.98</paragraph></td></tr>
<tr><td valign="top"><paragraph>1</paragraph></td><td valign="top"><paragraph>80</paragraph></td><td valign="top"><paragraph>45</paragraph></td><td valign="top"><paragraph>5.81</paragraph></td><td valign="top"><paragraph>3.31</paragraph></td><td valign="top"><paragraph>0.57</paragraph></td><td valign="top"><paragraph>0.40-0.82</paragraph></td></tr>
<tr><td valign="top"><paragraph>2</paragraph></td><td valign="top"><paragraph>35</paragraph></td><td valign="top"><paragraph>18</paragraph></td><td valign="top"><paragraph>8.92</paragraph></td><td valign="top"><paragraph>4.67</paragraph></td><td valign="top"><paragraph>0.52</paragraph></td><td valign="top"><paragraph>0.30-0.92</paragraph></td></tr>
<tr><td valign="top"><paragraph>≥3</paragraph></td><td valign="top"><paragraph>9</paragraph></td><td valign="top"><paragraph>6</paragraph></td><td valign="top"><paragraph>13.33</paragraph></td><td valign="top"><paragraph>7.58</paragraph></td><td valign="top"><paragraph>0.57</paragraph></td><td valign="top"><paragraph>0.20-1.59</paragraph></td></tr>
<tr><td valign="top"><paragraph><content stylecode="bold">5-Year Predicted Breast Cancer Risk (as calculated by the Gail Model)</content></paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>≤2.00%</paragraph></td><td valign="top"><paragraph>31</paragraph></td><td valign="top"><paragraph>13</paragraph></td><td valign="top"><paragraph>5.36</paragraph></td><td valign="top"><paragraph>2.26</paragraph></td><td valign="top"><paragraph>0.42</paragraph></td><td valign="top"><paragraph>0.22-0.81</paragraph></td></tr>
<tr><td valign="top"><paragraph>2.01-3.00%</paragraph></td><td valign="top"><paragraph>39</paragraph></td><td valign="top"><paragraph>28</paragraph></td><td valign="top"><paragraph>5.25</paragraph></td><td valign="top"><paragraph>3.83</paragraph></td><td valign="top"><paragraph>0.73</paragraph></td><td valign="top"><paragraph>0.45-1.18</paragraph></td></tr>
<tr><td valign="top"><paragraph>3.01-5.00%</paragraph></td><td valign="top"><paragraph>36</paragraph></td><td valign="top"><paragraph>26</paragraph></td><td valign="top"><paragraph>5.37</paragraph></td><td valign="top"><paragraph>4.06</paragraph></td><td valign="top"><paragraph>0.76</paragraph></td><td valign="top"><paragraph>0.46-126</paragraph></td></tr>
<tr><td valign="top"><paragraph>≥5.00%</paragraph></td><td valign="top"><paragraph>50</paragraph></td><td valign="top"><paragraph>19</paragraph></td><td valign="top"><paragraph>13.15</paragraph></td><td valign="top"><paragraph>4.71</paragraph></td><td valign="top"><paragraph>0.36</paragraph></td><td valign="top"><paragraph>0.21-0.61</paragraph></td></tr>
<tr><td valign="top"><paragraph>DCIS</paragraph></td><td valign="top"><paragraph>35</paragraph></td><td valign="top"><paragraph>23</paragraph></td><td valign="top"><paragraph>1.47</paragraph></td><td valign="top"><paragraph>0.97</paragraph></td><td valign="top"><paragraph>0.66</paragraph></td><td valign="top"><paragraph>0.39-1.11</paragraph></td></tr>
<tr><td valign="top"><paragraph><content stylecode="bold">Fractures (protocol-specified sites)</content></paragraph></td><td valign="top"><paragraph>92<footnote id="wherry1142943256304">Two women had hip and wrist fractures</footnote></paragraph></td><td valign="top"><paragraph>76<footnoteref idref="wherry1142943256304"></footnoteref></paragraph></td><td valign="top"><paragraph>3.87</paragraph></td><td valign="top"><paragraph>3.20</paragraph></td><td valign="top"><paragraph>0.61</paragraph></td><td valign="top"><paragraph>0.83-1.12</paragraph></td></tr>
<tr><td valign="top"><paragraph>Hip</paragraph></td><td valign="top"><paragraph>20</paragraph></td><td valign="top"><paragraph>9</paragraph></td><td valign="top"><paragraph>0.84</paragraph></td><td valign="top"><paragraph>0.38</paragraph></td><td valign="top"><paragraph>0.45</paragraph></td><td valign="top"><paragraph>0.18-1.04</paragraph></td></tr>
<tr><td valign="top"><paragraph>Wrist<footnote> Includes Colles' and other lower radius fractures</footnote></paragraph></td><td valign="top"><paragraph>74</paragraph></td><td valign="top"><paragraph>69</paragraph></td><td valign="top"><paragraph>3.11</paragraph></td><td valign="top"><paragraph>2.91</paragraph></td><td valign="top"><paragraph>0.93</paragraph></td><td valign="top"><paragraph>0.67-1.29</paragraph></td></tr>
<tr><td valign="top"><paragraph><content stylecode="bold">Total Ischemic Events</content></paragraph></td><td valign="top"><paragraph>59</paragraph></td><td valign="top"><paragraph>61</paragraph></td><td valign="top"><paragraph>2.47</paragraph></td><td valign="top"><paragraph>2.57</paragraph></td><td valign="top"><paragraph>1.04</paragraph></td><td valign="top"><paragraph>0.71-1.51</paragraph></td></tr>
<tr><td valign="top"><paragraph>Myocardial Infarction</paragraph></td><td valign="top"><paragraph>27</paragraph></td><td valign="top"><paragraph>27</paragraph></td><td valign="top"><paragraph>1.13</paragraph></td><td valign="top"><paragraph>1.13</paragraph></td><td valign="top"><paragraph>1.00</paragraph></td><td valign="top"><paragraph>0.57-1.78</paragraph></td></tr>
<tr><td valign="top"><paragraph>Fatal</paragraph></td><td valign="top"><paragraph>8</paragraph></td><td valign="top"><paragraph>7</paragraph></td><td valign="top"><paragraph>0.33</paragraph></td><td valign="top"><paragraph>0.29</paragraph></td><td valign="top"><paragraph>0.88</paragraph></td><td valign="top"><paragraph>0.27-2.77</paragraph></td></tr>
<tr><td valign="top"><paragraph>Nonfatal</paragraph></td><td valign="top"><paragraph>19</paragraph></td><td valign="top"><paragraph>20</paragraph></td><td valign="top"><paragraph>0.79</paragraph></td><td valign="top"><paragraph>0.84</paragraph></td><td valign="top"><paragraph>1.06</paragraph></td><td valign="top"><paragraph>0.54-2.09</paragraph></td></tr>
<tr><td valign="top"><paragraph>Angina<footnote>Requiring angioplasty or CABG</footnote></paragraph></td><td valign="top"><paragraph>12</paragraph></td><td valign="top"><paragraph>12</paragraph></td><td valign="top"><paragraph>0.50</paragraph></td><td valign="top"><paragraph>0.50</paragraph></td><td valign="top"><paragraph>1.00</paragraph></td><td valign="top"><paragraph>0.41-2.44</paragraph></td></tr>
<tr><td valign="top"><paragraph>Acute Ischemic Syndrome<footnote>New Q-wave on ECG; no angina or elevation of serum enzymes; or angina requiring hospitalization without surgery</footnote></paragraph></td><td valign="top"><paragraph>20</paragraph></td><td valign="top"><paragraph>22</paragraph></td><td valign="top"><paragraph>0.84</paragraph></td><td valign="top"><paragraph>0.92</paragraph></td><td valign="top"><paragraph>1.11</paragraph></td><td valign="top"><paragraph>0.58-2.13</paragraph></td></tr>
<tr><td valign="top"><paragraph><content stylecode="bold">Uterine Malignancies (among women with an intact uterus)</content><footnote id="wherry1142946110695">Updated long-term follow-up data (median 6.9 years) from NSABP P-1 study added after cut-off for the other information in this table.</footnote></paragraph></td><td valign="top"><paragraph>17</paragraph></td><td valign="top"><paragraph>57</paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Endometrial Adenocarcinoma<footnoteref idref="wherry1142946110695"></footnoteref></paragraph></td><td valign="top"><paragraph>17</paragraph></td><td valign="top"><paragraph>53</paragraph></td><td valign="top"><paragraph>0.71</paragraph></td><td valign="top"><paragraph>2.20</paragraph></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Uterine Sarcoma<footnoteref idref="wherry1142946110695"></footnoteref></paragraph></td><td valign="top"><paragraph>1</paragraph></td><td valign="top"><paragraph>4</paragraph></td><td valign="top"><paragraph>0.04</paragraph></td><td valign="top"><paragraph>0.17</paragraph></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Stroke<footnote>Seven cases were fatal; three in the placebo group and four in the NOLVADEX group</footnote></paragraph></td><td valign="top"><paragraph>24</paragraph></td><td valign="top"><paragraph>34</paragraph></td><td valign="top"><paragraph>1.00</paragraph></td><td valign="top"><paragraph>1.43</paragraph></td><td valign="top"><paragraph>1.42</paragraph></td><td valign="top"><paragraph>0.82-2.51</paragraph></td></tr>
<tr><td valign="top"><paragraph>Transient Ischemic Attack</paragraph></td><td valign="top"><paragraph>21</paragraph></td><td valign="top"><paragraph>18</paragraph></td><td valign="top"><paragraph>0.88</paragraph></td><td valign="top"><paragraph>0.75</paragraph></td><td valign="top"><paragraph>0.86</paragraph></td><td valign="top"><paragraph>0.43-1.70</paragraph></td></tr>
<tr><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Pulmonary Emboli<footnote>Three cases in the NOLVADEX group were fatal</footnote></paragraph></td><td valign="top"><paragraph>6</paragraph></td><td valign="top"><paragraph>18</paragraph></td><td valign="top"><paragraph>0.25</paragraph></td><td valign="top"><paragraph>0.75</paragraph></td><td valign="top"><paragraph>3.01</paragraph></td><td valign="top"><paragraph>1.15-9.27</paragraph></td></tr>
<tr><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Deep-Vein Thrombosis<footnote>All but three cases in each group required hospitalization</footnote></paragraph></td><td valign="top"><paragraph>19</paragraph></td><td valign="top"><paragraph>30</paragraph></td><td valign="top"><paragraph>0.79</paragraph></td><td valign="top"><paragraph>1.26</paragraph></td><td valign="top"><paragraph>1.59</paragraph></td><td valign="top"><paragraph>0.86-2.98</paragraph></td></tr>
<tr><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Cataracts Developing on Study<footnote id="wherry1142945317773">Based on women without cataracts at baseline (6,230-Placebo, 6,199-NOLVADEX)</footnote></paragraph></td><td valign="top"><paragraph>483</paragraph></td><td valign="top"><paragraph>540</paragraph></td><td valign="top"><paragraph>22.51</paragraph></td><td valign="top"><paragraph>25.41</paragraph></td><td valign="top"><paragraph>1.13</paragraph></td><td valign="top"><paragraph>1.00-1.28</paragraph></td></tr>
<tr><td valign="top"><paragraph>Underwent Cataract Surgery<footnoteref idref="wherry1142945317773"></footnoteref></paragraph></td><td valign="top"><paragraph>63</paragraph></td><td valign="top"><paragraph>101</paragraph></td><td valign="top"><paragraph>2.83</paragraph></td><td valign="top"><paragraph>4.57</paragraph></td><td valign="top"><paragraph>1.62</paragraph></td><td valign="top"><paragraph>1.18-2.22</paragraph></td></tr>
<tr><td valign="top"><paragraph>Underwent Cataract Surgery<footnote>All women (6,707-Placebo, 6,681-NOLVADEX)</footnote></paragraph></td><td valign="top"><paragraph>129</paragraph></td><td valign="top"><paragraph>201</paragraph></td><td valign="top"><paragraph>5.44</paragraph></td><td valign="top"><paragraph>8.56</paragraph></td><td valign="top"><paragraph>1.58</paragraph></td><td valign="top"><paragraph>1.26-1.97</paragraph></td></tr>
</tbody>
</table>